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ABSTRACT 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Does 
the addition of muramyl tripeptide to chemotherapy improve overall survival for patients with 
osteosarcoma?” 
 
STUDY DESIGN: Review of three English language primary randomized controlled trials 
published between 2005 and 2009.  
 
DATA SOURCES: Randomized controlled trials evaluating the addition of muramyl tripeptide 
(MTP) to chemotherapy for patients with osteosarcoma were found using Medline/PubMed 
databases.  
 
OUTCOMES MEASURED: Event-free survival (EFS) and overall survival were the outcome 
measures used to determine the effectiveness of the additional chemotherapy treatment in 
osteosarcoma patients. EFS was defined as the time from entry until an adverse event or last 
patient contact. Overall survival was defined as the time from entry until death or last patient 
contact.  
 
RESULTS: Three randomized controlled trials were included in this review.  A study by Meyers 
et al could not be analyzed according to its original factorial design due to an interaction between 
the study interventions. However, a follow up by Meyers et al, reported no evidence of 
statistically significant interaction between study interventions. The results demonstrated that the 
addition of MTP to chemotherapy resulted in a trend toward better EFS (p=.08), and improved 6-
year overall survival from 70% to 78% (p=.03).  Another study, by Chou et al, looked at the 
metastatic cohort from Intergroup Study 0133 in isolation, and found that the 5-year EFS for 
patients who received liposomal MTP was 42% versus 26% for those who did not (RR 0.72; 
p=.23; 95% CI). The 5-year OS for patients who received MTP versus no MTP was 53% and 
40% respectively (RR 0.72; p=0.27; 95% CI).  
 
CONCLUSION:  Based on these three trials, it is inconclusive if the addition of MTP to 
chemotherapy improves overall survival in patients with osteosarcoma.  The addition of MTP to 
chemotherapy has demonstrated a statistically significant improvement in overall survival, as 
well as a trend toward better EFS, but only in non-metastatic cohorts. The addition of MTP to 
chemotherapy did not achieve a statistically significant improvement in EFS or overall survival 
for those with metastatic osteosarcoma. Although the pattern of outcome was similar in all three 
studies, further research should be aimed at determining a particular chemotherapy plus MTP 
regimen and a specific patient population for which MTP is most effective.  
 
KEY WORDS: Osteosarcoma; Chemotherapy; Survival 
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INTRODUCTION 
 Osteosarcoma is the most common malignant primary bone tumor in children and 
adolescents1.  It is a malignant tumor of the bone in which the proliferating cells produce osteoid 
tissue or immature bone2.  The peak occurrence during the adolescent growth spurt indicates that 
a relationship exists between rapid bone growth and malignant transformation3.  Osteosarcoma 
occurs most frequently at sites where the greatest increase in length and size of bone occurs, with 
the metaphyses of long bones such as the femur being most commonly affected3.   
 The incidence of osteosarcoma is approximately 4.8 per million children younger than 20 
years of age1.  The annual incidence rate of osteosarcoma is quite variable. Incidence rate by age 
is approximately 0.3 per million in children under the age of 5 years, 2.8 per million between the 
ages of 5 and 9 years, 8.3 per million between the ages of 10 and 14 years, and 9.4 per million 
between the ages of 15 and 19 years1.  Approximately 400 new cases are reported each year in 
those under the age of 20 years in the United States1.  
 While an exact cost approximation has not been identified, the evaluation and treatment 
of osteosarcoma is quite complex.  Curative treatment approach to osteosarcoma involves both 
pre and post-op chemotherapy regimens lasting at least one year, surgical reconstructive 
procedures, frequent imaging modalities, lengthy inpatient hospital stays and complex 
rehabilitation programs.  In 2007, approximately 37.1 million dollars was spent on osteosarcoma 
research4.   
 The etiology of osteosarcoma is unknown.  The only well documented etiology is an 
environmental factor which is ionizing radiation exposure.1,5.  Radiation is implicated in 
approximately 2% of osteosarcomas.  Research suggests that a viral etiology may be responsible 
for bone sarcomas as evidenced by induction of cancer cells in response to viral factors or cell-
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free extracts of human osteosarcomas in the animal model1,5.  A genetic predisposition of 
osteosarcoma has been suggested, as several families have been identified to have multiple 
members with osteosarcoma5.  The strongest genetic predisposition has been found in patients 
with retinoblastoma.  In the hereditary form of this disorder, germline mutations of the 
retinoblastoma gene are common and most likely account for the increased frequency of 
secondary cancers in this population1.  In addition, germline mutations in the p53 gene can lead 
to a high risk of developing malignancies such as osteosarcoma, which has been described as the 
Li-Fraumeni syndrome1,5.  Individuals with syndromes such as Rothmund-Thomson syndrome 
and Werner and Bloom syndrome are also at high risk of developing osteosarcoma1. A history of 
disorders of bone metabolism, such as Paget disease and fibrous dysplasia, are also known 
predisposing factors in the development of osteosarcoma1.  
Early research reported that adjuvant chemotherapy had activity against both relapsed 
and metastatic osteosarcoma, demonstrating improved disease free survival rates 1,3. 
Chemotherapy is often administered prior to definitive surgery promoting an early attack on 
micrometastatic disease and tumor shrinkage, which aids in a limb preserving procedure3. The 
cytotoxic agents that have been shown to demonstrate the greatest efficacy in the treatment of 
osteosarcoma include high dose methotrexate, cisplatin, doxorubicin, and ifosfamide 1,3,6.   
Complete surgical resection of primary and metastatic disease is the cornerstone for 
successful treatment of osteosarcoma1.  Surgical management involves the complete resection of 
the tumor with a margin of uninvolved tissue and soft-tissue reconstruction1,3. Post surgical 
chemotherapy is typically continued until the patient has received 1 full year of treatment3.   
Osteosarcomas are highly radioresistant, thus radiotherapy has no role in its management3.  
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The addition of MTP to chemotherapy regimens may provide additional benefit to and 
improve the overall survival of patients newly diagnosed with osteosarcoma6,7,8.  Muramyl 
tripeptide (MTP) phosphatidylethanolamine (MTP-PE) is a synthetic lipophilic analog of 
muramyl dipeptide, and is a nonspecific immune modulator that is a synthetic analogue of a 
component of bacterial cell walls6,7,8.  MTP has been encapsulated in liposomes to target delivery 
to monocytes and macrophages to activate them to become tumoricidal6,7,8.  Preclinical studies 
have confirmed antitumor effects of MTP in rodents and canines with osteosarcoma 6.7,8.        
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “Does the 
addition of muramyl tripeptide to chemotherapy improve overall survival for patients with 
osteosarcoma?” 
METHODS 
 Meyers et al6, conducted a prospective randomized phase 3 trial for the treatment of 
newly diagnosed osteosarcoma in patients ≤ 30 years old.  This study compared the standard 3-
drug chemotherapy regimen (doxorubicin, cisplatin, and high-dose methotrexate) with the 
addition of ifosfamide6.  Additionally, patients were randomly assigned to receive MTP in 
conjunction with the assigned chemotherapy6.  The outcome measure used was event-free 
survival (EFS)6.  
With additional follow up and review of the previously mentioned trial, a report and 
update of the results were presented in a subsequent study by the same authors.  The primary end 
point for this analysis included both EFS and overall survival7.  In an additional study, Chou et 
al8 reported results for only those patients with metastatic disease who were enrolled in this trial, 
evaluating both EFS and overall survival.  
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 A detailed search was completed using Medline/PubMed databases with the key words: 
“osteosarcoma”, “chemotherapy”, and “survival”.  Articles selected were limited to English 
language peer reviewed publications between 2005 and 2009.  The criterion used for selection 
was based on their relevance and the importance of the outcome to the patient (POEMS). 
Inclusion criteria were randomized controlled trials based on patient oriented outcomes.  Studies 
excluded were those that included patients over the age of 30 years, patients who received prior 
chemotherapy or radiation, and individuals with non-resectable disease.  Refer to Table 1 for 
further information regarding demographics and study characteristics.  Relative risk and hazard 
ratios were evaluated to determine the relationship between treatment and overall and event free 
survival.  95% confidence intervals set and a p value of .05 was used to determine statistical 
significance between the variables of treatment and event free and overall survival.  
Table 1: Demographics and Characteristics of Included Studies 
Study Type # 
Pts 
Age Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Meyers6, 
2005 
RCT 677 0-30 Pts with 
histologically 
confirmed, high-
grade, 
intramedullary 
osteosarcoma. 
Adequate renal, 
hepatic, and 
cardiac function.  
Pts who received 
prior chemo or 
radiation.  
At Pediatric 
Oncology Group 
institutions, pts 
with clinically 
detectable 
metastatic disease 
were ineligible.  
Pts with > 30 d 
elapsed btwn 
diagnostic biopsy 
and enrollment.  
0 Addition of MTP to 
cisplatin, doxorubicin, 
and high dose 
methotrexate 
(HDMTX) or cisplatin, 
doxorubicin, HDMTX, 
and ifosfamide after 
tumor resection.  
 
Meyers7, 
2008 
RCT 662 0-30 Pts with 
histologically 
confirmed high-
grade 
intramedullary 
osteosarcoma.   
 
Clinically 
detectable 
metastatic 
disease. 
Non-resectable 
disease. 
 
0 Addition of MTP to 
cisplatin, doxorubicin, 
and high dose 
methotrexate 
(HDMTX) or cisplatin, 
doxorubicin, HDMTX, 
and ifosfamide after 
tumor resection.  
 
Jones, Muramyl Tripeptide & Osteosarcoma 5 
Chou8, 
2009 
RCT 91 0-30 Pts with 
histologically 
confirmed high-
grade 
intramedullary 
osteosarcoma. 
Pts with at least 
one site of 
metastasis.  
Pts with 
clinically 
detectable 
metastatic disease 
were not eligible 
at Pediatric 
Oncology Group 
institutions 
4 Addition of MTP to 
cisplatin, doxorubicin, 
and high dose 
methotrexate 
(HDMTX) or cisplatin, 
doxorubicin, HDMTX, 
and ifosfamide after 
tumor resection.  
 
 
OUTCOMES MEASURED 
 The outcomes measured were those of patient oriented evidence that matters (POEMS), 
which includes event free survival (EFS), defined as the time from entry until an adverse event 
or last patient contact6,7,8.  EFS after surgery was defined from the start of the first course of 
maintenance therapy until adverse event or last patient contact6,7,8.  Adverse events included 
progression of disease, diagnosis of a second malignant neoplasm, or death before disease 
progression or second malignant neoplasm 6,7.  However, Chou et al8, did not consider 
progression of the disease after induction an event, allowing these patients to remain in the study.  
Overall survival was a common outcome used by Meyers et al7 and Chou et al8, which was 
defined as the time from entry into the trial until death or last patient contact.  
 EFS and overall survival were estimated using the Kaplan-Meier method6,7,8.  The log-
rank test was used to assess the statistical significance of the comparisons of risk for adverse 
event6,7,8.  The stratified log-rank test was used to evaluate outcomes measured from the time of 
enrollment and involving randomized regimens6,7,8.  A relative hazards regression model with the 
characteristic of interest as the only variable in the model, was used to set up confidence 
intervals (CIs) and evaluate relative risk6,7,8.  In Meyers et al7 and Chou et al8, interaction 
between chemotherapy and biological agent was assessed using the relative hazards regression.       
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RESULTS 
 Three randomized controlled trials are analyzed in this review. The primary end point for 
the analysis of these studies was EFS and overall survival.  All results were presented in 
dichotomous form.  
Meyers et al6, reported that for patients without metastasis, EFS was 70% at 3 years and 
63% at 5 years from study entry6.  Original study design included a 2 X 2 factorial design for 
analysis.  However, secondary to an interaction between the two study interventions this model 
was not appropriate for analysis.  Regimen A- (cisplatin, doxorubicin, and HDMTX) was 
considered the standard arm of the trial6.   Regimen B- consisted of cisplatin, doxorubicin, and 
HDMTX with the addition of ifosfamide6.  Regimen B+ consisted of cisplatin, doxorubicin, and 
HDMTX with the addition of ifosfamide and MTP6.  These two regimens were compared to the 
standard arm in order to evaluate an interaction between treatments6.  Regimen B- resulted in a 
decreased EFS, while regimen B+ resulted in increased EFS6.  Detailed results of the four study 
arms are displayed in Table 2. 
Table 2-Relative Risk of Adverse Event According to Randomized Regimen 
Randomized 
Regimen 
# pts RR 95% CI P-value 
A- 172 1.0 -- .88 
A+ 168 1.0 0.71 to 1.5  
A- 172 1.0 -- .12 
B- 167 1.3 0.93 to 1.9  
A- 172 1.0 -- .22 
B+ 170 0.78 0.54 to 1.2  
 
Meyers et al7, conducted a follow up investigation of the addition of MTP to standard 
chemo based on their previous results and interactions observed.  The conclusion of the previous 
study did not change, however, based upon what was observed the authors were able to expand 
on the results and interactions observed.  Follow up analysis of the outcome for EFS and overall 
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survival did not identify a statistically significant interaction between the two interventions 
(p=.102)7.  
Meyers et al, reported an EFS of 66% at 4 years and 64% at 6 years from study entry7. 
When MTP was added to chemotherapy, EFS improved, but without statistical significance.  For 
all patients who were not assigned to receive MTP, 6 year EFS was 61%7.  In patients assigned 
to receive MTP the 6-year EFS was 67% (p=.08)7.  Additional results are displayed in Table 3.  
The addition of MTP to chemotherapy provided an enhanced overall survival.  Overall 
survival was reported as 81% at four years and 74% at six years from entry into the study7.  The 
addition of MTP to chemotherapy resulted in improvement in 6-year overall survival from 70% 
to 78% (p=.03; RR=0.71)7.  The authors believe that the improvement in overall survival, with 
median follow up of 7.7 years, can be attributed to the randomized addition of MTP to initial 
chemotherapy treatment7.  (Table 3)    
As displayed in Table 4 the hazard ratio for EFS for patients who received MTP was 
0.80 (95% CI, 0.62 to 1.0).  This does not meet an established p< .05 level of significance 
(p=.08)7. The relative risk of death for patients randomly assigned to receive MTP is 0.71 (95% 
CI, 0.52 to 0.96; p= .03)7.  Both chemotherapy regimens were associated with the same risk of 
death (p=.83)7.   
Table 3- EFS and Overall Survival According to Treatment Regimen 
Treatment Regimen EFS Probability (%) 
4 year                  6year 
Survival Probability 
4 year            6 year 
All patients 66                        64 81                  74 
Regimen A :Without MTP 
                     With MTP 
      66                        64 
65                        63 
              78                   71 
82                   75 
Regimen B: Without MTP 
                     With MTP 
      60                        58 
74                        71 
              77                   70 
86                   81 
Regimen A with or without MTP 65                        63 80                   73 
Regimen B with or without MTP 67                        64 82                   75 
Chemotherapy:  Without MTP 
          With MTP 
      63                       61 
69                       67 
             78                    70 
84                    78 
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Table 4- Analysis of Interaction of MTP 
 Hazard Ratio 95% CI 
Event Free Survival 
Regimen A 
Regimen B 
All patients 
 
0.99 
0.65 
0.80 
 
0.69 to 1.4 
0.45 to 0.93 
0.62 to 1.0 
Overall Survival 
Regimen A 
Regimen B 
All patients 
 
0.76 
0.66 
0.71 
 
0.49 to 1.2 
0.43 to 1.0 
0.52 to 0.96 
 
 In the study performed by Chou et al8, 91 patients from Intergroup Study 0133 with 
metastatic disease at initial diagnosis were analyzed.  As of August 2005, the 5-year EFS for this 
entire cohort of patients was 34% and the 5-year overall survival was 47%8.   Further detail 
regarding EFS and overall survival on each chemotherapy regimen is provided in Table 5.  For 
EFS, no statistical difference was identified among all regimens (log-rank= 0.55)8.  For overall 
survival there was no statistical difference among the regimens (log-rank= 0.60)8.  The relative 
risk for adverse event associated with assignment to receive MTP was 0.728.  The relative risk 
for death associated with assignment to receive MTP was 0.728. Further detail regarding relative 
risk of death and relative risk of adverse event is provided in Table 6.    
Table 5- EFS and Overall Survival According to Treatment Regimen 
 5 Year EFS 95% CI 5 Year Overall 
Survival 
95% CI 
All 34% 24 to 45 47%  35 to 58 
Regimen A 
without MTP 
 
29% 
 
11 to 51 
 
53% 
 
28 to 73 
Regimen A with 
MTP 
 
41% 
 
21 to 60 
 
50% 
 
26 to 69 
Regimen B 
without MTP 
 
23% 
 
8 to 43 
 
30% 
 
13 to 50 
Regimen B with 
MTP 
 
44% 
 
23 to 64 
 
57% 
 
33 to 75 
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Table 6-Relative Risks Based on Treatment Regimen 
 Relative Risk of Death Relative Risk of Adverse 
Event 
Regimen A 1.0 1 
Regimen B 1.1 1.07 
MTP 0.72 0.72 
No MTP 1.0 1.0 
 
 Treatment effects of all three studies are displayed in Table 7.  Number needed to treat 
(NNT) was calculated to describe the number that would need to be treated in order to prevent 
one additional adverse outcome as compared with the standard chemotherapy regimen of 
cisplatin, doxorubicin, and HDMTX.  The absolute benefit increase (ABI) represents the actual 
increase in positive outcomes between all treatment regimens and the control regimen.  The 
relative benefit increase (RBI) represents the increased chance of positive outcome in the 
treatment regimens compared to the chance of positive outcomes in the control regimen.   
Table-7 Comparisons of Dichotomous Data 
 CER EER RBI ABI NNT 
Meyer et al05 42 54 29 12 9 
Meyer et al 08 60 68 13 8 13 
Chou et al 42 54 29 12 9 
CER=Control Event Rate; EER=Experimental Event Rate; RBI=Relative Benefit Increase; 
ABI=Absolute Benefit Increase 
 
Most side effects of the addition of MTP were found to be mild to moderate in nature.  
Common side effects observed include: fever, chills, elevation in ALT, infections, anemia, and 
stomatitis6.  Most patients experienced fewer adverse events with time and subsequent 
administration.  
DISCUSSION 
In the randomized control trial conducted by Meyers et al6, the addition of MTP to a 
three-drug chemotherapy regimen including cisplatin, doxorubicin, and high dose methotrexate 
had no impact on EFS.  However, the addition of MTP to a four-drug chemotherapy regimen 
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including cisplatin, doxorubicin, high dose methotrexate, and ifosfamide resulted in more 
favorable EFS6.  Unfortunately, an observed interaction between ifosfamide and MTP 
invalidated the factorial design for the analysis of the impact of MTP on EFS.  Although 
comparison of the four treatment arms showed a possible improvement in EFS with the addition 
of MTP to chemotherapy, further clinical and laboratory investigation was required to explain 
the interaction between ifosfamide and MTP.   
With additional follow-up and further examination of the data reported in Meyers et al6 
Intergroup Study 0133, the authors reported additional results and conclusions of this trial.  Upon 
further exam, there was no statistically significant interaction between study interventions7.  The 
addition of MTP to chemotherapy resulted in improved 6 year overall survival from 70 to 78%7 
which was a statistically significant improvement in overall survival (p=.03).  Also, a trend 
toward improved EFS for patients with non-metastatic osteosarcoma was observed7. 
In the study performed by Chou et al8, patients with metastatic disease enrolled in 
Intergroup Study 0133, a trend toward improved EFS and overall survival with the addition of 
MTP to chemotherapy was observed, but was not statistically significant.  Secondary to the small 
number of patients included in the study cohort, precise estimation of treatment effect and 
conclusions about the differences between each study arm was not possible.  Additional, larger 
studies analyzing the effect of MTP to chemotherapy in patients with metastatic disease is 
required.   
The poor prognosis of patients diagnosed with osteosarcoma emphasizes the need for 
new cytotoxic agents to be identified and utilized in treatment.  Liposomal MTP-PE is an 
immune modulator that has been studied extensively in the treatment of osteosarcoma.  In 2009 
the European Medicines Agency (EMA) approved the use of MTP as a drug called Mifamurtide 
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for the treatment of high-grade, non-metastatic, resectable osteosarcoma in patients aged two to 
thirty years9.  The FDA denied approval of this drug in 20079.  Analysis and further, larger 
clinical trials regarding optimal dosing of MTP both before and after tumor resection, as well as 
usefulness in metastatic osteosarcoma is required. 
CONCLUSION  
 Based on the analysis of the three trials included in this review, it is inconclusive if the 
addition of MTP to chemotherapy improves overall survival in patients with osteosarcoma.  
 There is a pattern of outcome in favor of this multidrug regimen and results supporting its anti-
tumor effects in patients with non-metastatic osteosarcoma, however it is not clear if the results 
are clinically significant enough to warrant making major changes to management of this 
disease.  Further research should be aimed at inclusion of larger patient populations over longer 
periods of time, with use of a single chemotherapy regimen for both metastatic and non-
metastatic patients, and should address the optimal dosing schedule for MTP administration.  
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